X4 Pharmaceuticals, Inc. Common Stock XFOR

$2.83 -9.29% at last close
Market Cap$318.59 million
P/E Ratio—
Div Yield—
Volume672.3K
52-Week Range $2.43$4.83

Analyst Ratings

Consensus
Buy — 4 Buy · 0 Hold · 0 Sell (4 analysts)
Avg. Price Target
$11.25 (+297.5% upside)

Full XFOR forecast & analyst actions →

Key Stats

Today's Range
$2.82 – $3.13
50-Day Range
$2.43 – $4.13
52-Week Range
$2.43 – $4.83
Volume
672K shs
Average Volume
701K shs
Market Cap
$318.59 million
P/E Ratio
—
Dividend Yield
—

Short Interest

Short Interest
0.08%
Days to Cover
2.97

About X4 Pharmaceuticals, Inc. Common Stock

X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees
45
Exchange
XNAS
Listed
2017-11-16

Related Stocks

Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.